Nabriva Therapeutics plc (NBRVF)

Nabriva Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Market Capitalization	0	6	34	51	125	98
Market Cap Growth	-57.97%	-82.95%	-33.41%	-59.13%	27.61%	-55.43%
Enterprise Value	-2	-3	-10	19	83	-2
Last Close Price	0.00	1.89	14.97	60.50	330.00	365.00
PE Ratio	-	-0.09	-0.52	-0.45	-1.18	-0.65
PS Ratio	0.00	0.16	1.18	10.15	13.16	10.13
PB Ratio	-0.30	1.76	0.64	1.54	3.02	1.42
P/FCF Ratio	-0.37	-0.16	-0.57	-0.71	-1.73	-1.34
P/OCF Ratio	-0.37	-0.16	-0.57	-0.72	-1.74	-1.34
EV/Sales Ratio	0.12	-0.07	-0.35	3.77	8.71	-0.22
EV/EBITDA Ratio	-0.07	0.05	0.21	-0.29	-1.04	0.03
EV/EBIT Ratio	-0.07	0.05	0.21	-0.29	-1.04	0.03
EV/FCF Ratio	-0.27	0.07	0.17	-0.26	-1.15	0.03
Debt / Equity Ratio	-0.03	1.59	0.15	0.23	0.84	0.35
Debt / FCF Ratio	-0.04	-0.14	-0.13	-0.11	-0.48	-0.33
Asset Turnover	0.90	0.66	0.41	0.07	0.09	0.09
Inventory Turnover	-	3.90	2.54	4.88	-	-
Quick Ratio	0.25	0.69	2.70	2.44	5.35	6.04
Current Ratio	0.38	1.13	3.59	3.09	5.48	6.11
Return on Equity (ROE)	-602.21%	-201.91%	-114.36%	-186.76%	-150.61%	-152.33%
Return on Assets (ROA)	-92.85%	-61.56%	-43.53%	-54.18%	-48.58%	-49.91%
Return on Capital (ROIC)	-234.16%	-99.24%	-59.33%	-70.87%	-59.10%	-58.92%
Earnings Yield	-18351333.33%	-987.50%	-145.57%	-136.21%	-66.32%	-117.37%
FCF Yield	-4341333.33%	-637.59%	-175.40%	-140.06%	-57.65%	-74.60%
Buyback Yield / Dilution	-27.72%	-54.67%	-237.48%	-73.12%	-46.07%	-70.28%
Total Shareholder Return	-27.72%	-54.67%	-237.48%	-73.12%	-46.07%	-70.28%

Source: S&P Capital IQ. Standard template.